ClinicalTrials.gov
public full text
Public Domain
A Study of LY3819469 in Participants With Impaired and Normal Renal Function
The main purpose of this study is to assess the amount of study drug (LY3819469) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3819469 will also be evaluated in these participants. The study will last up to 17 weeks including screening period.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluation of Renal Drug Transport in Healthy Volunteers#321587
- Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects#832537
- Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects#1059961
- First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.#873478
- A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment#992529
Record · ID 1407805
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive